A Phase 1 study of palovarotene for dry eye disease
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2018
Price : $35 *
At a glance
- Drugs Palovarotene (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Clementia Pharmaceuticals
- 07 Nov 2018 According to a Clementia Pharmaceuticals media release, will be utilized to inform the design of a proof of concept trial evaluating palovarotene in dry eye disease (CTP300302).
- 02 Oct 2018 According to a Clementia Pharmaceuticals media release, data from this trial is expected in the first quarter of 2019.
- 02 Oct 2018 Status changed from planning to recruiting, according to a Clementia Pharmaceuticals media release.